(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...

In GSK’s suit against Pfizer, the British pharma was seeking monetary damages or royalties and potentially a permanent injunction on the commercialization of Pfizer’s RSV vaccine in the U.S.

GSK said in the lawsuit that Pfizer began working on its RSV program around 2013, at least seven years after GSK began developing its shot. Pfizer denied the allegations and argued GSK's patents ...

GSK) and rival Pfizer (NYSE:PFE) have agreed to end a lawsuit that alleged Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK’s patent rights in its competing RSV shot ...

The approval represents another step forward for Pfizer in the RSV vaccine market, where it competes with GSK’s Arexvy. While GSK has secured approval for older adults, it has not yet gained ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...

GSK filed suit in August 2023, alleging that Pfizer’s respiratory syncytial virus (“RSV”) vaccine, ABRYSVO, infringes four U.S. patents covering GSK’s rival RSV vaccine, AVREXY.

GSK's vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programme.

It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to have flown out of the traps more quickly than Pfizer’s rival shot Abrysvo in the first weeks since they ...